Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 3.
doi: 10.1186/s12876-025-04467-w. Online ahead of print.

Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study

Jin-Hu Chen #  1   2   3 , Zhi-Ming Cai #  1   2   4 , Zhen-Rong Yang #  4 , Tao Lin  4 , Shi-Chai Hong  1   2 , Xin-Cheng Su  4 , Yue-Ming Lin  3 , Lu Lin  4 , Zai-Sheng Ye  5 , Yong-Jian Zhou  6   7   8
Affiliations

Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study

Jin-Hu Chen et al. BMC Gastroenterol. .
No abstract available

Keywords: Gastric GIST; Gastrointestinal stromal tumor; Neoadjuvant imatinib; Rectal GIST; Survival; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This retrospective study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Fujian Medical University Union Hospital (Approval No. 2025KY086) and the Ethics Committee of Fujian Cancer Hospital (Approval No. K2025-166-01). Given the retrospective nature of the study and the use of anonymized data, the requirement for informed consent was waived by both ethics committees. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

References

    1. Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022;19(5):328–41.
    1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.
    1. Joensuu Heikki. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.
    1. Li J, Gong JF, Wu AW, et al. Post-operative Imatinib in patients with intermediate or high risk Gastrointestinal stromal tumor[J]. Eur J Surg Oncol. 2011;37(4):319–24.
    1. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant Imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.